Comments
Lupin has said the UK health regulator has completed the inspection of its Goa facility without making any critical observations.
In a BSE filing today, Lupin “announced the successful completion of the inspection by the UK MHRA at its Goa facility in March, 2018. There were no critical or major observations in the inspections’’.
“We are committed to maintaining truly global quality standards at our manufacturing units. The successful inspection by UK MHRA is a meaningful development for our Goa plant,” Lupin Managing Director Nilesh Gupta said.
Yesterday, Lupin had announced that its Pithampur unit 2 manufacturing facility located in Indore had been cleared by Health Canada after a review.
In November 2017, Lupin had received a warning letter from the US Food and Drug Administration for its manufacturing facilities in Goa and Pithampur, Indore. Shares of Lupin were trading up by 1.68 per cent at Rs 788.40 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.